Not for release, publication and/or distribution in or into the United States, Canada, Australia, Japan or any other jurisdiction where this is not allowed pursuant to local legal restrictions

Galapagos extends subscription period for shares Galapagos

Mechelen, Belgium, April 29, 2005 – Galapagos NV, a genomics-based drug discovery company, announces that it extends the subscription period for the intended capital increase and adjusts the price range and size of the offering. The subscription period will be open until Wednesday May 4, 2005, 16.00 hours CET, and the adjusted price range for the shares is € 7 to € 8.

Offering, over-allotment and listing

The adjusted offering comprises up to € 20 million in newly issued shares and up to 82,562 newly issued shares through the exercise of warrants. In relation to the offering, Galapagos has granted an over-allotment option to the lead managers to purchase up to an additional € 3 million in newly issued shares. Therefore the maximum number of the shares that will be issued is 3,368,276, including the over-allotment option. The shares will be placed through a public offering in both Belgium and the Netherlands in combination with an international private placement. Application for listing has been made on the Eurolist by Euronext Brussels and Euronext Amsterdam. Listing is expected on Friday May 6, 2005.

Subscription period and pricing

The subscription period for the shares has been extended until Wednesday May 4, 2005, 16.00 hours CET. The price for the shares is expected to be between € 7 and € 8. Subscriptions that have already been made will remain valid and investors may enter new subscriptions through their banks and/or revise their current subscriptions. The definitive price and the number of shares placed with investors will be determined and announced following the closing of the subscription period.

“Institutional and retail clients have shown broad interest in our floatation,” said Onno van de Stolpe, CEO of Galapagos. “This underlines that we have been able to convince investors of the strength of our message and our company. However, the IPO climate is currently difficult. We therefore believe that it is in the interest of all parties concerned to adjust the size of the capital increase and the price range. After these adjustments, the book is now strongly oversubscribed and we expect to place the shares successfully. Euronext regulations require us to extend the subscription period with another three days.”

Prospectus

The prospectus provides more information on Galapagos, the offer, and the risks with regard to investing in the shares of Galapagos. The announcement of the adjusted offering, in the Official List of Euronext Amsterdam d.d. May 2, 2005, and in one or more national newspapers in Belgium and the Netherlands, is part of the prospectus. The prospectus is available at Galapagos (Generaal De Wittelaan L11/A3, B-2800 Mechelen, Belgium, tel: +32 15 342 900), Galapagos Genomics BV (Archimedesweg 4, 2301 CA Leiden, The Netherlands, tel: +31 71 524 8800), KBC Securities (Havenlaan 12, 1080 Brussel, Belgium), Kempen & Co (Beethovenstraat 300, 1077 WZ, Amsterdam, The Netherlands, tel: +31 20 348 8500) and at the counters of all KBC Bank branches in Belgium. The electronic version of the prospectus is available at the company website of Galapagos, www.glpg.com, at the website of Euronext, www.euronext.com and at www.kbcsecurities.be.

For further information please contact:

Galapagos
Onno van de Stolpe, CEO
Tel: +32 15 342 900
Email: onno@galapagos.be
Internet: www.glpg.com

Smink, van der Ploeg & Jongsma
Financial Communication
Léon Melens, Kees Jongsma
Tel: +31 20 647 8181
Mob: +31 6 5381 6427
Email: lmelens@spj.nl

Not for release, publication or distribution in or into the United States, Canada, Australia, Japan or any other jurisdiction where this is not allowed pursuant to local legal restrictions. This announcement does not constitute an offer of securities in the United States or in any other jurisdiction.

The Galapagos shares have not been and will not be registered under the United States Securities Act of 1933 as amended (the Securities Act), or with any other securities regulatory authority of any State of the United States and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act (and applicable State securities laws). There will be no offer of Galapagos shares in the United States.